| NCT07015398 | A Study of the Pharmacokinetic Interaction Between Pirfenidone, Nintedanib, and Nalbuphine Extended Release (NAL ER) in Healthy Participants | RECRUITING | PHASE1 | 2025-06-30 | 2025-09 | 2025-09 |
| NCT07036029 | NAL ER IPF Respiratory Function and Safety Study | RECRUITING | PHASE1 | 2025-06 | 2025-10 | 2025-09 |
| NCT05964335 | Cough Reduction in IPF With Nalbuphine ER | COMPLETED | PHASE2 | 2024-02-06 | 2025-04-24 | 2025-04-24 |
| NCT05962151 | Refractory Chronic Cough Improvement Via NAL ER (RIVER) | COMPLETED | PHASE2 | 2023-11-30 | 2025-01-06 | 2025-01-06 |
| NCT04030026 | A Study of Nalbuphine (Extended Release) ER in Idiopathic Pulmonary Fibrosis (IPF) for Treatment of Cough | COMPLETED | PHASE2 | 2019-10-29 | 2022-05-27 | 2022-05-27 |
| NCT04020016 | Nalbuphine ER Effects of Liver Disease on Pharmacokinetics and Itch | UNKNOWN | PHASE1 | 2018-10-24 | 2020-12 | 2020-11 |
| NCT03497975 | PRISM Study-Pruritus Relief Through Itch Scratch Modulation | COMPLETED | PHASE2, PHASE3 | 2018-08-07 | 2023-02-24 | 2022-05-10 |
| NCT04018664 | Oral Abuse Potential Study of Nalbuphine | COMPLETED | PHASE1 | 2018-05-29 | 2020-06-02 | 2018-12-03 |
| NCT02174432 | Open Label Extension Study of Nalbuphine HCl ER in Patients With Prurigo Nodularis | COMPLETED | PHASE2, PHASE3 | 2015-08-15 | 2017-09-03 | 2017-09-03 |
| NCT02174419 | Study of Nalbuphine HCl ER Tablets in Patients With Prurigo Nodularis | COMPLETED | PHASE2, PHASE3 | 2015-03 | 2016-08 | 2016-08 |
| NCT02143973 | Open Label Extension Study of Nalbuphine HCl ER in Hemodialysis Patients With Uremic Pruritus | COMPLETED | PHASE2, PHASE3 | 2014-09 | 2016-01 | 2016-01 |
| NCT02143648 | Study of Nalbuphine HCl ER Tablets in Hemodialysis Patients With Uremic Pruritus | COMPLETED | PHASE2, PHASE3 | 2014-06 | 2015-07 | 2015-07 |
| NCT02373215 | Phase 1 Study of Nalbuphine HCl ER Tablets in Hemodialysis Patients With Uremic Pruritus | COMPLETED | PHASE1 | 2013-04 | 2013-11 | 2013-11 |